RHEKISS registry: SpA pts on bDMARDs at conception are NOT at inc. risk for adverse pregnancy outcomes. Discontinuation of bDMARDs after conception is assoc'd w/ inc. dz activity during/after pregnancy & flare risk. Abs 1730 #ACR21 #RheumNow @RheumNow https://t.co/b2wI9GZios https://t.co/wsuvv3hF0v

• Disease Activity and Outcome in Pregnancies of Patients with SpA - Data from th…

b/tsDMARDs + tumor response in rheum irAEs Excellent point by @CCalabreseDO @LCalabreseDO: - despite progression in 5/10, DMARD contribution uncertain (bad cancer) - without DMARD, ICI would have had to stop crucial question, prospective study needed #ACR21 ABST1519 @RheumNow https://t.co/omJnTNVscH

Sub-analysis of ICHIBAN study looking at adverse events in tocilizumab treated patients with/without steroids. Steroids associated with small increase in adverse events across board. Abstr#1693 #ACR21 @RheumNow https://t.co/ldiovirKpo

For patients with inflammatory irAEs, what's your preference of bDMARD/tsDMARD? (keeping in mind both irAE response and tumor response) #ACR21 irAE Study Group run by @CCalabreseDO @NAbdelwahabMD @ReidMDMPH @RheumNow

#ACR21 Ab#1655. Respiratory Ifn in RA on bDMARD ▶️1 group was initiated into vaccination program vs usual care ⭐️Vaccinated group had ⬇️ admissions from respiratory ifns. 44% ⬇️ severe resp ifn 💉programs work! @Rheumnow https://t.co/pljR6DbAtU https://t.co/goSHGID8qG

• https://bit.ly/3F3JkzH

#ACR21 Year In Review: Factors associated with #COVID deaths in pts with #RMD: ⛔️age, male, HTN/CVD, lung disease, steroid>10mg/d, ⬆️disease activity ⛔️RTX (OR: 4), SFZ (3.6), other IS (2.2), No DMARDs (2.1) vs MTX monotherapy as reference @RheumNow https://t.co/Zd6qXCtGLk https://t.co/YHBEelLqKB

• https://bit.ly/3GVBZE0

Avacopan (C5a inhibitor) is a new promising therapy for ANCA vasculitis. US FDA approved in Oct 2021 #ACR21 @rheumnow https://t.co/tWvKzHOT5V

Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi

Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care 🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide 🔹🚫significant diff 🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dose https://t.co/AYQFXqlubl #ACR21 Abst1288 @RheumNow

• First Year Infection Risk in SLE Patients Treated with Rituximab versus Standar…

SLE: Belimumab + standard rx significantly⬇️risk of severe flares vs placebo. Greatest in those with: 🔹+dsDNA 🔹low C3 or C4 🔹SLICC/ACR Damage index of 0 (argument for early treatment!) https://t.co/UcGXEklqwJ #ACR21 Abst#1295 @RheumNow

• Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across Multiple…

#ACR21 Ab#1445. RTX & #covid19 outcomes ⭐️RTX ass. w/ Upwards arrow COVID hospitalization, ICU admission, and ventilation ▶️We need huge caution in pts that have not been vax'ed before RTX 💉💉 @Rheumnow https://t.co/6UNUVhnBkI https://t.co/vHkQe9fZpI

• https://bit.ly/3qk9MB2

So what do we do with Iberdomide data? Tough to analyze re 2nd half of yr1 and uncertainty of dose response Abst#1458 #ACR21 @RheumNow v low placebo response 35% Interesting https://t.co/JXnoJTy2tv